Delafloxacin-Capped Gold Nanoparticles (DFX-AuNPs): An Effective Antibacterial Nano-Formulation of Fluoroquinolone Antibiotic
New antibiotics are seen as ‘drugs of last resort’ against virulent bacteria. However, development of resistance towards new antibiotics with time is a universal fact. Delafloxacin (DFX) is a new fluoroquinolone antibiotic that differs from existing fluoroquinolones by the lack of a protonatable sub...
Main Authors: | Amr Selim Abu Lila, Bader Huwaimel, Ahmed Alobaida, Talib Hussain, Zeeshan Rafi, Khalid Mehmood, Marwa H. Abdallah, Turki Al Hagbani, Syed Mohd Danish Rizvi, Afrasim Moin, Abobakr F. Ahmed |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-08-01
|
Series: | Materials |
Subjects: | |
Online Access: | https://www.mdpi.com/1996-1944/15/16/5709 |
Similar Items
-
Delafloxacin––A novel fluoroquinolone for the treatment of ciprofloxacin‐resistant Pseudomonas aeruginosa in patients with cystic fibrosis
by: Beverley Cherie Millar, et al.
Published: (2021-01-01) -
Delafloxacin: design, development and potential place in therapy
by: Candel FJ, et al.
Published: (2017-03-01) -
Evaluation of Delafloxacin against a Burkholderia pseudomallei Efflux Mutant Panel
by: Sandra P. McCurdy, et al.
Published: (2022-10-01) -
In Vitro Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and Ureaplasma Species
by: Yingying Kong, et al.
Published: (2022-06-01) -
Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial
by: Sandra McCurdy, et al.
Published: (2020-08-01)